Patient-derived tumor organoids (PDOs) closely preserve the cellular heterogeneity, histopathology, and molecular features of the original tumors, making them powerful preclinical models. Antisense oligonucleotides (ASOs) are an emerging class of precision medicines that modulate gene expression at the RNA level with h...
Thi Thom Tran, Thi Thuc Uyen Phan, M. Baboudjian et al.· Advanced Healthcare Material...· 0 citations
Metastasis-free survival (MFS) may not have the same meaning after radical prostatectomy (RP) and radiotherapy (RT), largely because RT is typically combined with prolonged androgen-deprivation therapy (ADT), which can delay the clinical emergence of metastases. Therefore, MFS benefits cannot be assumed to have the sam...
M. Baboudjian, Alessandro Uleri, G. Fallara et al.· European Urology Oncology· 0 citations
Management of advanced solid cancers remains challenging, particularly after the development of therapeutic resistance. Here, we synthesized a library of phosphonium-substituted 5-fluorouracil (5-FU) derivatives and evaluated their anticancer activity across multiple tumor models. Among fourteen compounds, EB-18 emer...
Quang Hieu Duong, E. Khusnutdinova, T. Le et al.· Journal of Experimental &...· 0 citations
Growing evidence suggests that AS appears oncologically safe in well-selected patients, and magnetic resonance imaging will play a key role in the appropriate selection and follow-up of patients.
Alessandro Uleri, L. Cella, T. Long-Depaquit et al.· BJU International· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.